- News
News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our five new HSO Fact Sheets.
Fact Sheet No. 100 (July 2022)
Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM)
Fact Sheet No. 101 (July 2022)
Asciminib (Scemblix®) for the treatment of Philadelphia chromosome?positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP)
Fact Sheet No. 102 (July 2022)
Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer
Fact Sheet No. 103 (July 2022)
Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)
Fact Sheet No 104 (July 2022)
Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Shared Decision Making (SDM) wird zur Realität
- Perkutane koronare Interventionen (PCI) bei chronischen Komplettverschlüssen (CTO)
- His-bundle-pacing zur Stimulation des kardialen Reizleitungssystems
- Mikrowellenablation (MWA) bei Lebertumoren
- Chemosaturation mit perkutaner Leberperfusion für Patient*innen mit Leberkrebs
- Lebervenen- und Pfortaderembolisation vor einer Major-Leberresektion
- Hypoglossusnerv-Stimulation für Patient*innen mit mittlerer bis schwerer obstruktiver Schlafapnoe
- Koronarsinus-Reducer bei refraktärer Angina Pectoris
- Subkutan implantierbarer Kardioverter-Defibrillator
- Gastroösophagealer Reflux (GERD): Laparoskopische Behandlungen mit magnetischem Speiseröhren-Ring, elektrischer Stimulationstherapie, RefluxStop™
- Termine
- Themen-Vorschau
Announcement
Evaluation of individual medical procedures - Reports 2022
We are pleased to introduce our new reports.
Decision Support Documents 2022:
- DSD 130: Hepatic and portal vein embolisation prior to major hepatectomy: https://eprints.aihta.at/1390
- DSD 131: Microwave ablation for liver tumours: https://eprints.aihta.at/1391
- DSD 132: His-bundle-pacing for patients requiring a permanent pacemaker or cardiac resynchronisation: https://eprints.aihta.at/1392
- DSD 133: Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer: https://eprints.aihta.at/1393
- DSD 134: Lower Esophageal Sphincter Devices for Laparoscopic Surgery in Patients with Gastroesophageal Reflux Disease (GERD): https://eprints.aihta.at/1394
+ 4 Updates:
- DSD 64: Percutaneous coronary interventions (PCI) for chronic total occlusion (CTO). Update 2022: https://eprints.aihta.at/1386
- DSD 100: Stimulation der oberen Atemwege bei mittelschwerer bis schwerer Schlafapnoe. Update 2022: https://eprints.aihta.at/1387
- DSD 109: Subcutaneous implantable cardioverter-defibrillator (S-ICD): 1. Update 2022: https://eprints.aihta.at/1388
- DSD 121: Percutaneous transvascular implantation of a coronary sinus reducing stent: Update 2022: https://eprints.aihta.at/1389
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v22 June/July2022)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Chronische Wunden und evidenzbasierte Versorgungsplanung
- Horizon Scanning zu Gentherapien: CAR-T Zelltherapien und ATMPs (Update 2022)
- Pränatale Screening- und diagnostische Tests auf fetale Anomalien: Regulierung und Finanzierung in ausgewählten europäischen Ländern
- Telemedizin in der Diabetesversorgung in Österreich
- Closed-loop Systeme bei Typ 1 Diabetes mellitus
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our two new HSO Fact Sheets.
Fact Sheet No. 98 (June 2022)
Selinexor (Nexpovio®) in and dexamethasone for the treatment of multiple myeloma (MM)
Fact Sheet No. 99 (June 2022)
Pembrolizumab (Keytruda) as monotherapy for the adjuvant treatment of stage IIb IIc III melanoma
Announcement
ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022
This report is an update of a previous Horizon Scanning report from 2020, which identified 32 ATMPs. Since August 2020, six of these new ATMPs have been approved by the EMA and five more will be decided by 2023. According to market analyses, 535 ATMPs will be investigated in phase 1 to 3 in 2022, with a further 1,451 in preclinical stages. Coagulation factor VIII (haemophilia A) remains the most common target for non-oncology indications and coagulation factor IX (haemophilia B) has risen to become the second most common indication.
To answer the questions, a systematic search of trial registries was conducted to identify gene therapies and ATMPs in development, followed by extraction of data on identified ongoing clinical trials (limited to phase 2/3 and 3), complemented by a search of the EMA database of medicines under assessment to identify those therapies that are close to approval. Published information on the products and the current development/regulatory status was then collected and subsequently converted into short "vignettes".
Publication: Policy Brief No. 006b: https://eprints.aihta.at/1383
Contact: Ozren Sehic
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v21 April/ May 2022)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Horizon Scanning Initiativen: IHSI, CADTH, NIHR-IO, nationale Aktivitäten
- Trends bei Artificial Intelligence (AI)
- Trends bei Augmented - und Virtual Reality (AR, VR)
- Trends bei Connected Devices and Wearables
- Trends in der Kardiologie
- Trends bei Neuromodulation und Neurostimulation
- Trends in der regenerativen Medizin
- HSS zu Diabetesversorgung
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our six new HSO Fact Sheets.
Fact Sheet No. 86 (April 2022)
Ciltacabtagene autoleucel (Carvykti®) for the treatment of multiple myeloma (MM)
Fact Sheet No. 87 (April 2022)
Cabozantinib (Cabometyx®) as monotherapy for the treatment of thyroid carcinoma (DTC)
Fact Sheet No. 88 (April 2022)
Tisagenlecleucel (Kymriah®) for the treatment of follicular lymphoma (FL) after two or more lines of systemic therapy
Fact Sheet No. 89 (April 2022)
Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of B-cell lymphoma (DLBCL)
Fact Sheet No. 90 (April 2022)
Pembrolizumab (Keytruda®) as monotherapy in adults with colorectal cancer
Fact Sheet No. 91 (April 2022)
Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for cervical cancer
